Log ind
COLOURBOX6429704.jpg
Foto: Colourbox

New lawsuit creates more uncertainty for Novo Nordisk

Top picks in English:

Novo Nordisk has been met with a number of lawsuits this month, the latest announced this week. But although it happens at a bad time for the hard-tried company, it will not have a material impact on its business, according to one analyst.


BY LOUISE WENDT JENSEN
Offentliggjort 31.01.17 kl. 16:01

Log ind for at læse artikler

Velkommen til MedWatch. En del af vores indhold er eksklusivt og forbeholdt vores brugere.

Prøv os gratis i 14 dage

Få fuld adgang til vores kvalitetsjournalistik med et gratis prøveabonnement.

Sign up for MedWatch newsletter
Mest læste Top picks in English

“You have to remember that investment is a long-term business”

Kasim_Kutay.jpg Top picks in English:

Although its asset value and net result both dipped significantly in 2016, the new CEO of Novo A/S, Kasim Kutay, is very optimistic on behalf of the company. The long-term trend looks good, he says, and the company is ready to increase investments and bridge the gap between two of its units.

Biotech and CRO outfit Gubra continues explosive growth

Top picks in English:

Thanks to a successful gamble on one particular niche, Denmark’s Gubra has managed to quadruple its employee base in just a few years. The two-pronged business is set to expand significantly in the future.

Novo Nordisk jumps on the discount wagon

Top picks in English:

Novo Nordisk’s US unit has struck a deal with CVS Health for a new savings program that will give some patients up to 80 percent reduction on some of the group’s insulin products. It thus looks like times are changing in the Denmark-based insulin giant.

Here is what Danish drug companies pay their workers

Top picks in English:

The average monthly salary in the private pharmaceutical industry in Denmark is DKK 57,109. Make the jump to find out which company pays the highest wages and learn how much the rest of the industry pays as well.

“We’ll be a meaningful player, even in the lung market"

Top picks in English:

US-based pharma group Bristol-Myers Squibb has come under pressure in the field of immuno-oncology, but the company’s CFO believes they are still in a strong position, also in the all-important lung cancer niche. He is open to looking at external innovation in one particular area.

Cytovac continues partner search

Top picks in English:

The Danish biotech company Cytovac headed to the BIO-Europe conference in Barcelona hoping to attract potential partners to help it advance its lead asset.

Forsiden lige nu

Etac-chef efter "fantastisk" år: Det offentlige er blevet mere kvalitetsbevidst

Annett Axelsen Toft-Olsen.jpg Medico & Rehab:

Den danske Etac-afdeling har afsluttet 2016 med en særdeles pæn vækst og føler, at indkøbsfolkene i regioner og kommuner er blevet mere lydhøre overfor andre argumenter end pris. Til gengæld er Etacs chef nervøs for resten af branchen.

Dansk Aktionærforening: "Novo-bestyrelsen har fejlet"

Medicinal & Biotek:

Hos Dansk Aktionærforening mener man ikke, at bestyrelsen i Novo Nordisk har været sin opgave voksen, og man presser på for at få formand Göran Ando til at takke af.

Fruergaard: Vi skal være bedre til at tilpasse os

Medicinal & Biotek:

Novos Nordisks nye topchef mener selv, at han er kommet godt fra start. Udfordringen er fortsat USA, og der er masser af hårdt arbejde forude i et fortsat svært 2017.

Lundbeck et skridt nærmere EU-godkendelse af nøgleprodukt

Medicinal & Biotek:

Danske Lundbeck er nu et skridt tættere en godkendelse i Europa af skizofrenimidlet Rexulti, der er et af selskabets fem nøgleprodukter.

Medie: Dandrit misser fusion

Medicinal & Biotek:

Biotekselskabet opgiver amerikanske fusionsplaner, skriver Børsen. Bestyrelsesformand melder, at Dandrit er tæt på en afklaring.

ATP stærkt utilfreds med Novo-præstation - efterlyser opkøb

Medicinal & Biotek:

Novo Nordisk-toppen er udmærket klar over, at 2016 var et forfærdeligt år for aktionærerne. Pensionskassen ATP var bestemt heller ikke tilfreds.

ANNONCE
ANNONCE


ANNONCE